Lawyers predict that FDA’s proposed rule to enable generic manufacturers to unilaterally change their labeling to include new safety information will give the plaintiffs bar a weapon to pursue new claims against both generic and brand name companies.
Erin Bosman, a partner at Morrison & Foerster, noted that the majority of courts have found that complaints can be...